

Effective Date		5/1/2024
Coverage Polic	y Number	1802

Step Therapy – Value and Advantage Prescription Drug Lists (Employer Group Plans)

Table of Contents

Related Coverage Resources

Overview	1
Coverage Policy	1
References	7

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

Employer Group Plans have a Prescription Drug List that subjects certain brand name drugs to step therapy requiring medical necessity review.

Coverage Policy

Cigna approves coverage for these brand name drugs as medically necessary when there is a documented failure, inadequate response, contraindication per FDA label, or intolerance to the number of Step 1 and/or Step 2 drugs, or as otherwise specified in the table below.

Step Therapy (ST) definitions:

- **Step 1 Medications –** These medications do not require Step Therapy, are automatically covered, and do not require prior authorization.
- **Step 2 Medications** Usually brand name medications. These medications do not require Step Therapy, are automatically covered, and do not require prior authorization.

Page 1 of 7

• **Step 3 Medications** – Usually brand name medications. These medications require Step Therapy. If the physician determines the treatment plan should begin with a Step 3 medication, a request for authorization will need to be submitted and approved.

(Note: Not all plans will use all Step Therapy classes in the table below. Where noted, certain benefit plans may require different numbers of alternatives as prerequisite therapy.)

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Note: Receipt of sample product does not satisfy any criteria requirements for coverage.

Cigna Employer Group Plans: Value and Advantage Prescription Drug Lists

	Antidoprossants	.g	
	Antidepressants		
Complete Plan: Requires THREE Step 1 agents unless specified below			
Essential Plan: Requires THREE Step 1 agents unless specified below Limited Plan: N/A			
Step 1 Medications Step 2 Medications Step 3 Medications			
bupropion (Wellbutrin/Wellbutrin)	Otep 2 incurcations	Fetzima	
SR/Wellbutrin XL)		Sarafem	
 citalopram (generic Celexa) 		Garatem	
 desvenlafaxine succ ER (generic Pristiq) 			
duloxetine (generic Cymbalta)			
escitalopram (generic Lexapro)			
fluoxetine (generic Prozac/Prozac			
Weekly/Sarafem)			
fluvoxamine			
paroxetine (generic Paxil/Paxil CR)			
sertraline (generic Zoloft)			
venlafaxine/venlafaxine er (generic			
Effexor/Effexor XR)			
vilazodone (generic Viibryd)			
An exception to the criteria will be provided wher	n an individual is not a candidate	e for (e.g., stabilized condition where	
therapeutic interchange is inappropriate) the Ste	p Therapy requirements.		
Anti	-Parkinsonism Drugs		
Complete P	lan: Requires ONE Step 1 age	ent	
	Essential Plan: N/A		
	Limited Plan: N/A		
Step 1 Medications	Step 2 Medications	Step 3 Medications	
		. Vadaga	
selegiline Attention Defice	sit I by nove of ive Discussion (Xadago (ADUD)	
Attention Deficit Hyperactive Disorder (ADHD)			
Complete Plan: N/A			
Essential Plan: Requires FOUR Step 1 agents Limited Plan: N/A			
Step 1 Medications Step 2 Medications Step 3 Medications			
amphetamine sulfate (generic Evekeo)		Adderall	
amphetamine/dextroamphetamine (generic)		Evekeo	
Adderall)		Focalin	
, ,		Ritalin	

Page 2 of 7

Coverage Policy Number: 1802

amphetamine/dextroamphetamine ER Zenzedi (generic Adderall XR) d-amphetamine (generic Dexedrine/Dextrostat) dexmethylphenidate (generic Focalin) dexmethylphenidate ER (generic Focalin dextroamphetamine (generic Zenzedi) lisdexamfetamine dimesylate capsules or chewable tablets (generic for Vyvanse) methamphetamine (generic Desoxyn) methylphenidate (generic Ritalin) methylphenidate CD/ER/LA/SA (generic Ritalin LA/Concerta) mixed salts of a single-entity amphetamine product extended-release capsules (generic for Mydayis)

An exception to the criteria will be provided when an individual is not a candidate for (e.g., stabilized condition where therapeutic interchange is inappropriate) the Step Therapy requirements.

Atypical Antipsychotic Agents Complete Plan: Requires ONE Step 1 agent Essential Plan: Requires ONE Step 1 agent Limited Plan: N/A

	Step 1 Medications	Step 2 Medications	Step 3 Medications
•	aripiprazole (generic Abilify)		Caplyta
•	clozapine (generic Clozaril)		Fanapt
•	clozapine ODT (generic Fazaclo)		Invega
•	lurasidone (generic Latuda)		Rexulti
•	olanzapine/olanzapine ODT (generic		Risperdal/Risperdal M – Effective
	Zyprexa/Zyprexa Zydis)		until 6/30/2024
•	paliperidone (generic Invega)		Saphris
•	pimozide		Secuado Patch
•	quetiapine (generic Seroquel)		Seroquel
•	quetiapine ER (generic Seroquel XR)		Seroquel XR
•	risperidone (generic Risperdal/Risperdal		Vraylar
	M)		
•	risperidone ODT		
•	ziprasidone (generic Geodon)		

An exception to the criteria will be provided when an individual is not a candidate for (e.g., stabilized condition where therapeutic interchange is inappropriate) the Step Therapy requirements.

*An exception to the Step Therapy requirement criteria may be provided if individual has documented inability to take tablet formulations

Diabetes Care		
Complete Plan: Requires ONE Step 1 agent		
Essential Plan: Requires ONE Step 1 agent		
Limited Plan: N/A		

Step 1 MedicationsStep 2 MedicationsStep 3 Medications• metformin• Farxiga
• Glyxambi
• Janumet
• Janumet XR
• Januvia

Page 3 of 7

Coverage Policy Number: 1802

Jardiance
Jentadueto
Jentadueto XR
Synjardy
Synjardy XR
Tradjenta
Trijardy XR
Xigduo XR

Note: The metformin step requirement criteria applies to new starts only.

An exception to Step Therapy criteria will be provided when ONE of the following are met:

- 1. The patient will be initiating dual therapy with metformin AND Farxiga or Jardiance, approve Farxiga or Jardiance.
- 2. The patient has a contraindication to metformin, according to the prescriber, approve Farxiga or Jardiance. Note: Examples of contraindications to metformin include acute or chronic metabolic acidosis, including diabetic ketoacidosis.
- 3. If the patient has heart failure with reduced ejection fraction, approve Farxiga or Jardiance.
- 4. If the patient has heart failure with preserved ejection fraction, approve Farxiga or Jardiance.
- 5. If the patient has chronic kidney disease, approve Farxiga or Jardiance.
- 6. If the patient has atherosclerotic cardiovascular disease or, according to the prescriber, the patient has at least two risk factors for cardiovascular disease, approve Farxiga or Jardiance.

risk factors for cardiovascular disease, approve Farxiga or Jardiance.			
Fibrates-Standard Dose Complete Plan: Requires THREE Step 1 agents Essential Plan: N/A Limited Plan: N/A			
Step 1 Medications	Step 2 Medications	Step 3 Medications	
 fenofibrate: 120mg, 150mg, 160mg fenofibrate micronized: 130mg, 134mg, 200mg fenofibrate nanocrystallized: 145mg fenofibric acid 105mg fenofibric acid DR 135mg 		 Fibricor 105 Mg Tablet Lipofen 150 Mg Capsule Tricor 145 Mg Tablet Trilipix DR 135 Mg Capsule Triglide 	
Fibrates-Low Dose Complete Plan: Requires THREE Step 1 agents Essential Plan: N/A Limited Plan: N/A			
Step 1 Medications	Step 2 Medications	Step 3 Medications	
 fenofibrate: 40mg, 50mg, 54mg fenofibrate micronized: 43mg, 67mg fenofibrate nanocrystallized: 48mg fenofibric acid 35mg fenofibric acid DR 45mg 		 Fibricor 35 Mg Tablet Lipofen 50 Mg Capsule Tricor 48 Mg Tablet Trilipix DR 45 Mg Capsule 	
Hypnotics			
Complete Plan: Requires ONE Step 1 agent Essential Plan: Requires ONE Step 1 agent Limited Plan: N/A			
Step 1 Medications	Step 2 Medications	Step 3 Medications	
 doxepin (generic Silenor) eszopiclone (generic Lunesta) ramelteon (generic Rozerem) 		DayvigoSonata	

Page 4 of 7

Coverage Policy Number: 1802

zaleplon (generic Sonata) zolpidem (generic Ambien and Intermezzo) zolpidem er (generic Ambien CR) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Complete Plan: Requires TWO Step 1 agents **Essential Plan: Requires TWO Step 1 agents** Limited Plan: N/A **Step 1 Medications Step 2 Medications Step 3 Medications** celecoxib (generic Celebrex) Anaprox DS diclofenac (generic Voltaren/Voltaren-Arthrotec 50 XR/Cataflam) Arthrotec 75 diclofenac/misoprostol (generic Arthrotec) Celebrex etodolac (generic Lodine/Lodine XL) Daypro fenoprofen calcium 600mg EC-Naprosyn flurbiprofen (generic Ansaid) Feldene ibuprofen (generic Motrin) Lodine indomethacin (generic Indocin/Indocin SR) Mobic ketoprofen (generic Oruvail) 50mg, 75mg Nalfon 600mg meclofenamate sodium Naprosyn tablets mefenamic acid **Qmiiz ODT** meloxicam (generic Mobic) Voltaren nabumetone Voltaren XR naproxen tablets (generic Naprosyn/EC-Naprosyn/Anaprox) oxaprozin (generic Daypro) piroxicam (generic Feldene) sulindac (generic Clinoril) tolmetin (generic Tolectin/Tolectin DS) Non-Steroidal Topical Complete Plan: Requires ONE Step 1 agent **Essential Plan: Requires ONE Step 1 agent** Limited Plan: N/A **Step 2 Medications Step 1 Medications** Step 3 Medications pimecrolimus cream (generic for Elidel Eucrisa cream) tacrolimus ointment (generic for Protopic) prescription topical corticosteroid An exception to Step Therapy criteria will be provided when the following is met: Individual is less than 2 years of age Osteoporosis Complete Plan: Requires ONE Step 1 agent **Essential Plan: Requires ONE Step 1 agent** Limited Plan: N/A **Step 1 Medications Step 2 Medications** Step 3 Medications Actonel alendronate (generic Fosamax) ibandronate (generic Boniva) Atelvia risedronate (generic Actonel and Atelvia) **Binosto** Boniva

Fosamax Plus D

Respiratory			
Step 1 Medications	Step 2 Medications	Step 3 Medications	
Inhaled Corticosteroid (ICS) with Long-Acting Beta Agonist (LABA) Complete Plan: Requires ONE Step 1 Essential Plan: Requires ONE Step 1 Limited Plan: N/A			
Wixela Inhub/fluticasone-salmeterol (Generic Advair Diskus)		AirDuo Digihaler	
Topical Inflammatory Complete Plan: Requires THREE Step 1 agents Essential Plan: Requires THREE Step 1 agents Limited Plan: N/A			
Step 1 Medications	Step 2 Medications	Step 3 Medications	
	lammatory, Very High Potenc	у	
 betamethasone dipropionate, augmented 0.05% gel, ointment, lotion clobetasol propionate 0.05% cream, foam, oint, gel, lotion, shampoo, soln, spray fluocinonide 0.1% cream halobetasol propionate 0.05% cream, ointment 		 Bryhali Lotion Clodan Diprolene Temovate Ultravate cream, ointment 	
Topic	al Inflammatory, High Potency	1	
 amcinonide 0.1% cream, lotion, ointment betamethasone dipropionate 0.05% ointment betamethasone dipropionate, augmented 0.05% cream desoximetasone 0.05% gel, ointment desoximetasone 0.25% cream, ointment, spray fluocinonide 0.05% cream, gel, ointment, solution triamcinolone acetonide 0.5% cream, ointment 		 Topicort 0.05% Gel, Ointment Topicort 0.25% Cream, Ointment, Spray 	
Topical In	flammatory, Medium Potency		
 betamethasone dipropionate 0.05% cream, lotion, spray betamethasone valerate 0.1% cream, foam clocortolone pivalate 0.1% cream desoximetasone 0.05% cream fluocinolone acetonide 0.025% cream, ointment fluocinonide 0.05% cream (emollient base) fluticasone propionate 0.005% ointment, cream, lotion hydrocortisone butyrate 0.1% cream, lotion, ointment, solution hydrocortisone valerate 0.2% cream, ointment 		 Cloderm Luxiq Synalar Topicort 0.05% Cream Dermasorb TA Dermatop Elocon 	

Page 6 of 7 Coverage Policy Number: 1802

 mometasone furoate 0.1% cream, lotion, ointment prednicarbate 0.1% cream, ointment triamcinolone acetonide 0.025% cream, lotion, ointment triamcinolone acetonide 0.1% cream, lotion, ointment 		
Topical	Inflammatory, Low Potency	
 alclometasone dipropionate 0.05% cream and ointment betamethasone valerate 0.1% lotion desonide 0.05% cream, lotion, ointment, gel fluocinolone acetonide 0.01% cream, oil, solution hydrocortisone cream, lotion, ointment 		 Ala-Scalp Capex Shampoo Derma-Smoothe-FS Dermasorb HC Desonate Nucort Scalacort DK Synalar Synalar TS Texacort

References

- 1. McEvoy GK, ed. AHFS 2017 Drug Information. Bethesda, MD: American Society of Health-Systems Pharmacists, Inc. Available from Stat!Ref, Teton Data Systems, Inc.
- 2. Drug Facts and Comparisons. Facts & Comparisons® eAnswers [online]. Available from Wolters Kluwer Health, Inc.
- 3. U.S. Food and Drug Administration. Drugs@FDA. U.S. Department of Health & Human Services: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
- 4. U.S. Food and Drug Administration. Drugs@FDA. U.S. Department of Health & Human Services: Vyvanse https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021977s045,208510s001lbl.pdf
- 5. U.S. Food and Drug Administration. FDA List of Authorized Generic Drugs: How Drugs are Developed and Approved:
 - http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/ucm126389.htm
- 6. U.S Food and Drug Administration. Generic Drugs Questions and Answers: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2024 Cigna.